8-AZAPROSTAGLANDIN DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT
申请人:ONO PHARMACEUTICAL CO., LTD.
公开号:EP1481976A1
公开(公告)日:2004-12-01
An 8-azaprostaglandin represented by formula (I)
(wherein all symbols have the same meanings as described in the specification), a pharmaceutically acceptable salt thereof or a cyclodextrin clathrate thereof. Since the compound represented by formula (I) binds to EP2 subtype among PGE receptor strongly, it is useful for preventive and/or treatment for immune diseases, allergic diseases, neuronal cell death, dysmenorrhea, premature birth, abortion, baldness, retinal neuropathy such as glaucoma, erectile dysfunction, arthritis, pulmonary injury, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, hepatic injury, acute hepatitis, liver cirrhosis, shock, nephritis, renal failure, circulatory diseases, systemic inflammatory response syndrome, sepsis, hemophagocytosis syndrome, macrophage activation syndrome, still disease, Kawasaki Disease, burn, systemic granuloma, ulcerative colitis, Crohn disease, hypercytokinemia at dialysis, multiple organ failure, or bone diseases etc.
由式(I)代表的 8-氮杂
前列腺素
(其中所有符号的含义与说明书中所述相同)、其药学上可接受的盐或其
环糊精凝块。慢性阻塞性肺病、肝损伤、急性肝炎、肝硬化、休克、肾炎、肾功能衰竭、循环系统疾病、全身炎症反应综合征、败血症、嗜血细胞增多综合征、巨噬细胞活化综合征、静止病、川崎病、烧伤、全身性肉芽肿、溃疡性结肠炎、克罗恩病、透析时的高细胞血症、多器官功能衰竭或骨病等。